Dahm, Anders Erik Astrup (2021) Cancer and Thrombosis: New Treatments, New Challenges. Medical Sciences, 9 (2). p. 41. ISSN 2076-3271
medsci-09-00041.pdf - Published Version
Download (284kB)
Abstract
The direct-acting oral anticoagulant (DOAC) has become an alternative to low-molecular-weight heparin (LMWH) for treatment and prophylaxis of venous thromboembolism (VTE) in cancer patients. The clinicians are, however, faced with difficult decisions regarding DOAC treatment: Which patients cannot use DOACs? Should incidental VTE be treated similar to symptomatic VTE? Is it safe to give DOACs to patients with gastrointestinal or urogenital cancers? How about drug–drug interactions? Should all cancer patients receive thromboprophylaxis? Is arterial thrombosis a problem? The current article reviews the available literature regarding these questions and aims to provide practical solutions based on data from the clinical trials and new guidelines.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | cancer; thrombosis; treatment; prophylaxis; anticoagulation |
Subjects: | Library Eprints > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 11 Nov 2022 04:50 |
Last Modified: | 07 Aug 2024 06:10 |
URI: | http://news.pacificarchive.com/id/eprint/91 |